EuroPCR 2022 | 1 Year Outcomes of Tricuspid Valve Repair with Cardioband: Feasibility Study

Tricuspid failure is a prevalent valvulopathy most often mistreated. It has been associated with high surgical risk and medical treatment has showed substandard therapeutic effect.

EuroPCR 2022 | Cambios en el daño cardíaco luego del reemplazo valvular aórtico por cirugía

Surgical repair with valve annuloplasty is the technique of choice for its long-term durability. Transcatheter repair of the tricuspid valve is an alternative that aims at imitating annuloplasty by reducing annulus diameter to facilitate better valve coaptation. 

A multicenter single arm study was conducted aiming at assessing the effectiveness and safety of the Cardioband safety system in the treatment of functional tricuspid failure

37 patients with tricuspid failure were included, at least moderate, symptomatic despite optimal medical treatment, with appropriate anatomy for the procedure. 

Primary end point was absence of adverse events associated to the procedure at 30 days, followed up for one year.  

Read also: EuroPCR 2022 | The IMPROVED-CTO Trial.

Patients were mean age 78±7.5, 76% were women, all of them presented severe tricuspid failure (60% torrential) and 73% pulmonary hypertension. 

When looking at major cardiovascular events, there was 8% cardiovascular mortality (unrelated to the procedure) mainly high rate of severe bleeding, both at 30 days (21%) and one year (35%), and 10% of rehospitalization for cardiac failure. 

The technique was shown effective, with 21% tricuspid annulus diameter reduction, which meant 73% reduction in tricuspid failure moderate to severe. Functional class was also improved (dyspnea in functional class CF I or II in 92% of patients).

Conclusions

Tricuspid repair with Cardioband showed high survival rate with low number of hospitalizations for cardiac failure. At one-year followup, there was significant tricuspid failure reduction and improved quality of life compared to baseline values. 

Dr. Omar Tupayachi

Dr. Omar Tupayachi.
Member of the Editorial Board of SOLACI.org.

Source: Presented by Late-breaking clinical trial en EuroPCR 2022 por Dr William Gray.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

TEER plus optimal medical therapy versus medical therapy alone in functional mitral regurgitation

Mitral regurgitation (MR) is a highly prevalent valvular heart disease that, in advanced stages and when left untreated, is associated with reduced quality of...

VECTOR: First Percutaneous Aorto-Coronary Bypass Case, a New Conceptual Approach

Coronary obstruction represents one of the most severe complications associated with transcatheter aortic valve implantation, particularly in valve-in-valve scenarios involving surgical bioprostheses, narrow aortic...

Is it safe to use negative chronotropic drugs early after TAVI?

TAVI is associated with a relevant incidence of conduction system disturbances and the development of atrioventricular block that may require permanent pacemaker implantation. Many...

Transapical TMVR in High Risk Patients: Intrepid 5-Year Outcomes

Moderate to severe mitral valve regurgitation (MR) continues is still a high prevalence condition with bad prognosis, particularly among the elderly with left ventricular...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Morpheus Global Registry: Safety and efficacy of the long tapered BioMime™ Morph stent in complex coronary lesions

Percutaneous coronary intervention in long coronary lesions continues to represent a technical and clinical challenge, in which the use of conventional cylindrical stents may...

TEER plus optimal medical therapy versus medical therapy alone in functional mitral regurgitation

Mitral regurgitation (MR) is a highly prevalent valvular heart disease that, in advanced stages and when left untreated, is associated with reduced quality of...

Hybrid Coronary Revascularization versus Conventional Bypass Surgery in Left Main Coronary Artery Disease

Significant left main coronary artery (LMCA) disease continues to represent a therapeutic challenge, particularly in patients with complex multivessel disease and high SYNTAX scores,...